Limb-Girdle Muscular Dystrophy (LGMD) - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035

Limb-Girdle Muscular Dystrophy (LGMD) Market Outlook

Thelansis's "Limb-Girdle Muscular Dystrophy (LGMD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Limb-Girdle Muscular Dystrophy treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Limb-Girdle Muscular Dystrophy (LGMD) Overview

Limb-Girdle Muscular Dystrophy is a heterogeneous group of inherited myopathies caused by mutations affecting sarcolemmal, sarcomeric, or nuclear proteins, driving progressive proximal muscle degeneration. Patients present with shoulder and pelvic girdle weakness, waddling gait, and variable cardiac or respiratory involvement; laminopathy and sarcoglycanopathy subtypes carry particular arrhythmia risk requiring early pacemaker or ICD consideration. Diagnosis combines elevated CK, muscle biopsy immunohistochemistry, and genetic panel testing. While no universal cure exists, the paradigm is shifting toward genotype-targeted therapies, including AAV-based gene therapy and glycosylation-pathway modulators under active evaluation. Physiotherapy, orthotic support, and cardiorespiratory surveillance remain foundational. Multidisciplinary care preserves function and quality of life.

Key Highlights

• In France, prevalent LGMD cases are projected to increase from approximately 1,402 in 2025 to 1,499 by 2035.
• LGMD remains a rare genetic neuromuscular disorder associated with progressive muscle weakness and disability.
• Improved genetic testing is facilitating earlier diagnosis and subtype identification.
• Significant unmet need persists due to the absence of broadly effective disease-modifying therapies.
• Emerging gene therapy and genetic medicine approaches are reshaping the treatment landscape.

Market Overview

• The France LGMD market is projected to grow from approximately $170 MN to $510 MN by 2035.
• Market growth is supported by:
• Advancements in gene therapy development
• Increasing adoption of precision diagnostics and supportive care
• Market expansion is expected to be driven by high-value rare disease therapies.
• Future growth will depend on successful commercialization of gene-based and disease-modifying treatments.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Sarepta Therapeutics, Inc.
• ML Bio Solutions, Inc.
• AskBio Inc.
• Atamyo Therapeutics